141 related articles for article (PubMed ID: 20684610)
1. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
[TBL] [Abstract][Full Text] [Related]
2. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
[TBL] [Abstract][Full Text] [Related]
4. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
[TBL] [Abstract][Full Text] [Related]
5. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
[TBL] [Abstract][Full Text] [Related]
7. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Hu Q; Negri M; Jahn-Hoffmann K; Zhuang Y; Olgen S; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Bioorg Med Chem; 2008 Aug; 16(16):7715-27. PubMed ID: 18674917
[TBL] [Abstract][Full Text] [Related]
9. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
Pinto-Bazurco Mendieta MA; Negri M; Hu Q; Hille UE; Jagusch C; Jahn-Hoffmann K; Müller-Vieira U; Schmidt D; Lauterbach T; Hartmann RW
Arch Pharm (Weinheim); 2008 Oct; 341(10):597-609. PubMed ID: 18720339
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
12. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
13. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
[TBL] [Abstract][Full Text] [Related]
14. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer.
Njar VC; Kato K; Nnane IP; Grigoryev DN; Long BJ; Brodie AM
J Med Chem; 1998 Mar; 41(6):902-12. PubMed ID: 9526564
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
Wang M; Fang Y; Gu S; Chen F; Zhu Z; Sun X; Zhu J
Eur J Med Chem; 2017 May; 132():157-172. PubMed ID: 28350999
[TBL] [Abstract][Full Text] [Related]
16. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
Emmerich J; Hu Q; Hanke N; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6022-32. PubMed ID: 23869452
[TBL] [Abstract][Full Text] [Related]
17. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.
Hu Q; Negri M; Olgen S; Hartmann RW
ChemMedChem; 2010 Jun; 5(6):899-910. PubMed ID: 20437447
[TBL] [Abstract][Full Text] [Related]
18. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
Hu Q; Yin L; Ali A; Cooke AJ; Bennett J; Ratcliffe P; Lo MM; Metzger E; Hoyt S; Hartmann RW
J Med Chem; 2015 Mar; 58(5):2530-7. PubMed ID: 25711516
[TBL] [Abstract][Full Text] [Related]
19. Imidazopyridyl compounds as aldosterone synthase inhibitors.
Whitehead BR; Lo MM; Ali A; Park MK; Hoyt SB; Xiong Y; Cai J; Carswell E; Cooke A; MacLean J; Ratcliffe P; Robinson J; Bennett DJ; Clemas JA; Wisniewski T; Struthers M; Cully D; MacNeil DJ
Bioorg Med Chem Lett; 2017 Jan; 27(2):143-146. PubMed ID: 27979595
[TBL] [Abstract][Full Text] [Related]
20. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
